Mindfulness-based intervention for benzodiazepine deprescription in hemodialysis patients with anxiety and depressive symptoms

Nicolas Garel, MD*; Christina Rigas*; Mona Ben m’rad, MD; Katie Bodenstein, BSc; Richa Joobear, MD, PhD; Harmehr Sekhon, PhD†; Soham Rej MD, MSC†

A 35-year-old female hemodialysis (HD) patient with end-stage renal disease was able to successfully withdraw from benzodiazepines, which had been prescribed for managing psychiatric and pain symptoms, following a mindfulness-based stress reduction (MBSR) intervention. The patient, who had been undergoing HD since the age of 6 years, enrolled in an MBSR program for HD patients consisting of 20- to 40-minute sessions over 8 weeks centred on breath work and directing attention to physical sensations (body scan) and thoughts. The sessions were delivered via Zoom during HD by an MBSR-certified psychologist.

The patient had a long-standing history of mild depressive, anxiety, insomnia, restless leg syndrome (RLS) and chronic pain symptoms. In addition to polypharmacy for HD, she had been regularly taking a benzodiazepine since the age of 20 years, clonazepam 0.75 mg twice daily for her anxiety and RLS, as well as citalopram 40 mg/d for her depressive symptoms, quetiapine 75 mg nightly for her insomnia, pregabalin 150 mg nightly for her pain symptomatology and pramipexole 0.5 mg/d for her RLS. The patient had previously tried to discontinue her benzodiazepine use by her own initiative and with the help of a psychiatrist, but was unsuccessful. This discontinuation was attempted with a gradual taper of approximately 10% of her dose every 2–3 weeks. Unfortunately, the discontinuation was unsuccessful because of resulting rebound anxiety and insomnia.

After the 8-week MBSR program, the patient reported experiencing a substantial decrease in her anxiety, pain and depressive symptoms. Most notably, after her previously unsuccessful attempts at discontinuing benzodiazepines, she was finally able to do so. She slowly decreased her dose by 0.125 mg weekly and successfully withdrew from clonazepam over 12 weeks following the MBSR program by using the breathing techniques she learned for managing the withdrawal symptoms. Furthermore, she reported successful self-management of insomnia, chronic pain and RLS without benzodiazepines for more than 18 months following the program. She reported practising daily mindfulness meditation for 5–10 minutes per day at least 4 days per week. Through this practice, she developed the capability to face new health challenges and difficult emotions by calming down with the breath and detaching herself from worries and negative self-talk.

Patients undergoing HD commonly experience symptoms of stress (29%), anxiety (12%–52%), depression (25%) and chronic pain (60%). Restless leg syndrome is also common in these patients and is associated with the accumulation of uremic solutes and toxins that are not completely removed during renal replacement therapy, generating substantial levels of discomfort and suffering. Benzodiazepines are one of the most prescribed drugs worldwide, and are given to 8%–26% of HD patients without any precise data on adverse events and their efficacy in this population. They are prescribed for their anxiolytic properties, insomnia and mild cases of RLS. Benzodiazepines act as positive allosteric modulators of the activity of the main inhibitory neurotransmitter of the central nervous system, γ-aminobutyric acid (GABA), producing sedative and anxiolytic effects, muscle relaxation and the interruption of seizures. International guidelines recommend ideally only short courses of benzodiazepines, as long-term use is associated with physical and psychological dependence; cognition decline and increased risk of falls, car accidents and possibly dementia.

Benzodiazepine withdrawal is associated with distressing symptoms, including tachycardia, headache, flu-like symptoms, nausea, vomiting and diarrhoea, paresthesia, muscle rigidity, sensory hypersensitivity, anxiety, agitation, panic attacks, depression, irritability and insomnia. Physiologic dependence occurs after 3–6 weeks of regular use. Predictive factors of severe withdrawal include short half-life, longer duration of use, high chronic doses, use of multiple benzodiazepines and rapid discontinuation. Currently, there are few strategies to promote benzodiazepine discontinuation in the general population, but none for HD patients. The most useful nonpharmacological interventions targeting withdrawal symptoms have been relaxation techniques and cognitive behavioural therapy in addition to gradual tapering of the medication. Although mindfulness interventions have not been studied in benzodiazepine deprescribing, they have shown promising results in opioid dose reduction in individuals with chronic pain, opioid withdrawal and cravings, by increasing self-control. Furthermore, a recent meta-analysis of mindfulness-based interventions in patients with cancer reported positive results on alleviating sleep disturbance and decreasing benzodiazepine use.

Mindfulness meditation has been shown to alleviate stress and anxiety through neurobiological mechanisms, including the modification of large-scale
functional networks and neurotransmission patterns. Furthermore, meditation has been found to improve emotion regulation through increased activation of the prefrontal cortex, decreased amygdala activation and increased GABA neurotransmission in GABAergic interneurons, which modulate cortical excitability. Therefore, mindfulness-based interventions may have a therapeutic impact for benzodiazepine prescription. A systematic review of mindfulness treatments for substance misuse disorders (e.g., mindfulness-based relapse prevention, mindfulness-oriented recovery enhancement, Vipassana meditation) found that, although each mindfulness-based therapy differed, the main components of mindfulness were used in each: paying attention to one’s present experience with a non-judgmental and accepting attitude, and cultivating bodily awareness, attention and emotion regulation. However, it cannot be concluded that a specific kind of mindfulness therapy is best for substance overuse, and thus a personalized approach may be most beneficial.

Given the prevalence of benzodiazepine use with knowledge gaps on their safety and efficacy for anxiety, insomnia and RLS as well as polypharmacy in this vulnerable HD population, our patient’s case illustrates mindfulness-based interventions as a potential adjunctive behavioural intervention for symptom management and benzodiazepine deprescribing in HD patients, which could be further investigated in future clinical trials.

*Share first authorship. tShare senior authorship.

Affiliations: From McGill University, Psychiatry residency & Clinician Investigator programs, Montréal, Que. (Garel); McGill University, Department of Psychiatry, Montréal, Que. (Rigas, Ben m’rad; Bodenstein); the Haut-Richelieu Hospital, Nephrology Department, Saint-Jean-sur-Richelieu, Que. (Ben m’rad); McGill University, Douglas Mental Health University Institute, Montréal, Que. (Joobear); McGill University, Jewish General Hospital (Sekhon); McGill University, Jewish General Hospital, Montréal, Que. (Rej).

Competing interests: Christina Rigas is supported by a CGS-CIHR Master’s Award. Mona Ben m’rad has received honoraria from the Régie de l’assurance maladie du Québec; speaker fees and consulting fees from Otsuka; speaker fees from CSK; and equipment, materials, gifts or “other” from Abbott and Otsuka. She has also received consulting fees from Creative Research Design and has contributed to the e-learning platform Nephrons and Neurons, which is funded by Otsuka. She serves as an unpaid consultant to Health Canada on the advisory board on renal adverse effects of COVID-19 transmission. Harmehr Sekhon is supported by postdoctoral fellowship awards from CIHR, Mitacs and AGEWELL. Soham Rej receives salary support from a Fonds de Recherche Québec – Santé (FRQS) clinician-scientist award, has received operating grants from Mitacs, is on a steering committee for AbbVie, and has shares in Alief Health. No other competing interests were declared.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Cite as: J Psychiatry Neurosci 2023 May 12;48(3):10.1503/jpn.220216

References